GlassScriptPhysician profile
Sandra J Spiers
NPI 1518167949
$1,794.70
in general payments reported to CMS, 2019-2025
15 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $450 · 2022: $351 · 2023: $617 · 2024: $165 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $731.29 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $438.65 | 2021-2025 | Caplyta |
| Noven Therapeutics, LLC | $172.72 | 2021-2025 | Xelstrym, Secuado |
| Lundbeck LLC | $145.19 | 2022-2025 | Abilify Maintena, Rexulti |
| Supernus Pharmaceuticals, INC. | $54.32 | 2022 | |
| Alkermes, INC. | $51.64 | 2022-2025 | Lybalvi |
| Idorsia Pharmaceuticals US INC | $38.19 | 2023-2025 | Quviviq, Quviviq |
| Sunovion Pharmaceuticals INC. | $33.72 | 2022 | |
| Neurocrine Biosciences, INC. | $32.44 | 2024-2025 | Ingrezza |
| Corium, LLC | $24.83 | 2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $16.62 | 2022 | |
| Noven Pharmaceuticals, INC. | $15.97 | 2021 | |
| Adlon Therapeutics L.P. | $14.02 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.95 | 2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Spiers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.